These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. Belotto-Silva C; Diniz JB; Malavazzi DM; Valério C; Fossaluza V; Borcato S; Seixas AA; Morelli D; Miguel EC; Shavitt RG J Anxiety Disord; 2012 Jan; 26(1):25-31. PubMed ID: 21907540 [TBL] [Abstract][Full Text] [Related]
5. An adolescent male with multiple paraphilias successfully treated with fluoxetine. Galli VB; Raute NJ; McConville BJ; McElroy SL J Child Adolesc Psychopharmacol; 1998; 8(3):195-7. PubMed ID: 9853694 [TBL] [Abstract][Full Text] [Related]
6. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder. Besiroglu L; Çetinkaya N; Selvi Y; Atli A Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. Alonso P; Menchon JM; Pifarre J; Mataix-Cols D; Torres L; Salgado P; Vallejo J J Clin Psychiatry; 2001 Jul; 62(7):535-40. PubMed ID: 11488364 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of combination of fluoxetine and cognitive behavioral therapy and fluoxetine alone for the treatment of obsessive compulsive disorder. Giasuddin NA; Nahar JS; Morshed NM; Balhara YP; Sobhan MA Pak J Pharm Sci; 2013 Jan; 26(1):95-8. PubMed ID: 23261733 [TBL] [Abstract][Full Text] [Related]
9. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Simpson HB; Gorfinkle KS; Liebowitz MR J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976 [TBL] [Abstract][Full Text] [Related]
10. Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study. Anand N; Sudhir PM; Math SB; Thennarasu K; Janardhan Reddy YC J Anxiety Disord; 2011 Oct; 25(7):939-45. PubMed ID: 21689902 [TBL] [Abstract][Full Text] [Related]
11. A 5-year prospective follow-up study of patients with obsessive-compulsive disorder treated with serotonin reuptake inhibitors. Cherian AV; Math SB; Kandavel T; Reddy YC J Affect Disord; 2014 Jan; 152-154():387-94. PubMed ID: 24157088 [TBL] [Abstract][Full Text] [Related]
12. Obsession of pregnancy: Does it exist? Faye A; Kirpekar V; Tadke R; Gawande S; Bhave S Asian J Psychiatr; 2017 Oct; 29():89-90. PubMed ID: 29061437 [No Abstract] [Full Text] [Related]
13. The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience. Eapen V; Trimble MR; Robertson MM Prog Neuropsychopharmacol Biol Psychiatry; 1996 May; 20(4):737-43. PubMed ID: 8843495 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of comorbid obsessive-compulsive and depressive disorders in children age]. Goriunov AV; Lobacheva MV Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(11 Pt 2):48-52. PubMed ID: 23257756 [TBL] [Abstract][Full Text] [Related]
16. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
17. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder. Neziroglu F; Yaryura-Tobias JA; Walz J; McKay D J Child Adolesc Psychopharmacol; 2000; 10(4):295-306. PubMed ID: 11191690 [TBL] [Abstract][Full Text] [Related]
18. Psychosocial treatment for obsessive-compulsive disorder. Munford PR; Hand I; Liberman RP Psychiatry; 1994 May; 57(2):142-52. PubMed ID: 7938333 [TBL] [Abstract][Full Text] [Related]
19. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Meltzer H; Bastani B; Jayathilake K; Maes M Neuropsychopharmacology; 1997 Jul; 17(1):1-11. PubMed ID: 9194044 [TBL] [Abstract][Full Text] [Related]
20. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. da Conceição Costa DL; Shavitt RG; Castro Cesar RC; Joaquim MA; Borcato S; Valério C; Miguel EC; Diniz JB J Psychiatr Res; 2013 Nov; 47(11):1700-7. PubMed ID: 23948637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]